Categories
Change Password!
Reset Password!
Orally administered SHR0302 is
effective and has good tolerability in people with atopic dermatitis.
According to the findings of phase II randomized clinical trial, people having moderate to severe atopic dermatitis attain considerable improvements in clinical symptoms, including pruritus, and improvement of skin lesions after oral administration of SHR0302 4 mg and 8 mg. Yan Zhao et al. and other researchers undertook this analysis for exploring safety and efficacy of SHR0302 (an oral and highly selective Janus kinase 1 inhibitor) for the management of dermatitis.
This placebo-controlled, double-blind, and multicenter study incorporated 105 Chinese adults having atopic dermatitis and who were intolerant or nonresponsive to conventional or topical systemic therapies. Participants (age 18-75 years) were randomized to receive SHR0302 4 mg once daily (n=35), SHR0302 8 mg once daily (n=35), or placebo (n=35) for twelve weeks.
The percentage of people attaining Investigator's Global Assessment (IGA) response (IGA of 0 or 1 [clear or almost clear] with an improvement of ≥2 grades) at 12th week was the major outcome ascertained. The secondary outcomes ascertained were pruritus numerical rating scale (NRS), and Eczema Area and Severity Index (EASI).
Table 1 denotes the percentage of people reporting IGA response at Week 12, EASI75, NRS ≥3-point improvement, and treatment-emergent adverse events.
The American Journal of Clinical Dermatology
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
Yan Zhao et al.
Comments (0)